Back to today’s briefing

Story perspectives

Spinogenix Launches Phase 2 Trial for Schizophrenia Pill

3/31/2025

49 3

Summary

Story summary

Spinogenix has launched open enrollment for a groundbreaking phase 2 trial of SPG302, a once-daily pill designed to combat schizophrenia. With FDA approval in hand, this innovative treatment seeks to regenerate synapses, offering hope to patients struggling with symptoms that current medications fail to alleviate. Christoph Correll highlights its transformative potential for schizophrenia care.

1 of 1

Story summary

Spinogenix has launched open enrollment for a groundbreaking phase 2 trial of SPG302, a once-daily pill designed to combat schizophrenia. With FDA approval in hand, this innovative treatment seeks to regenerate synapses, offering hope to patients struggling with symptoms that current medications fail to alleviate. Christoph Correll highlights its transformative potential for schizophrenia care.